Please assess the completion status of the following clinical trial:

Trial Title: A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Signed informed consent prior to any study-mandated procedure.~2. Male and female subjects aged from 18-85 years, inclusive.~3. For women of childbearing potential: Negative urine pregnancy test at Visit 1 and at Visit 2 before randomization.~4. Stable Coronary artery disease (CAD) defined by the presence of any of the following conditions:~   1. History of CAD with coronary artery stenosis on coronary angiogram ≥50%.~  2. Previously documented myocardial infarction occurring more than 3 months prior to randomization.~5. Antiplatelet background therapy stable for at least 1 month prior to randomization.~6. Body weight ≥ 40.0 kg (88.2 lbs).~Main Exclusion Criteria:~1. Acute coronary syndrome, percutaneous coronary intervention or any intervention for peripheral artery disease within 3 months prior to randomization.~2. Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to randomization.~3. Active internal bleeding, or medical history of recent (\< 1 month) bleeding disorders or conditions associated with high risk of bleeding (e.g., clotting disturbances, gastrointestinal bleed, hemoptysis).~4. Hemoglobin ≤ 10 g/dL at screening.~5. Loss of at least 250 mL of blood within 3 months of screening.~6. Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior to screening (Visit 1).~7. Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand disease).~8. Pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Selatogrel 8 mg (Type: EXPERIMENTAL): Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
- Selatogrel 16 mg (Type: EXPERIMENTAL): Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.

Based on this trial design, predict the completion outcome and termination type (if applicable).